Flying under the radar: the new wave of BCR–ABL inhibitors
Top Cited Papers
- 1 October 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 6 (10), 834-848
- https://doi.org/10.1038/nrd2324
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsProceedings of the National Academy of Sciences of the United States of America, 2006
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2006
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences of the United States of America, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998